Reinier G S Meester1, Ann G Zauber2, Chyke A Doubeni3, Christopher D Jensen4, Virginia P Quinn5, Mark Helfand6, Jason A Dominitz7, Theodore R Levin4, Douglas A Corley4, Iris Lansdorp-Vogelaar8. 1. Department of Public Health, Erasmus MC University Medical Center, Rotterdam, Netherlands. Electronic address: r.meester@erasmusmc.nl. 2. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York. 3. Department of Family Medicine and Community Health and Department of Epidemiology, Perelman School of Medicine, and Leonard Davis Institute of Health Economics and Center for Public Health Initiatives, University of Pennsylvania, Philadelphia, Pennsylvania. 4. Kaiser Permanente Division of Research, Oakland, California. 5. Kaiser Permanente Southern California, Research and Evaluation, Pasadena, California. 6. Veterans Affairs Portland Healthcare System, Portland, Oregon. 7. Veterans Affairs Puget Sound Healthcare System, Seattle, Washington; Division of Gastroenterology, University of Washington School of Medicine, Seattle, Washington. 8. Department of Public Health, Erasmus MC University Medical Center, Rotterdam, Netherlands.
Abstract
BACKGROUND & AIMS: Delays in diagnostic testing after a positive result from a screening test can undermine the benefits of colorectal cancer (CRC) screening, but there are few empirical data on the effects of such delays. We used microsimulation modeling to estimate the consequences of time to colonoscopy after a positive result from a fecal immunochemical test (FIT). METHODS: We used an established microsimulation model to simulate an average-risk United States population cohort that underwent annual FIT screening (from ages 50 to 75 years), with follow-up colonoscopy examinations for individuals with positive results (cutoff, 20 μg/g) at different time points in the following 12 months. Main evaluated outcomes were CRC incidence and mortality; additional outcomes were total life-years lost and net costs of screening. RESULTS: For individuals who underwent diagnostic colonoscopy within 2 weeks of a positive result from an FIT, the estimated lifetime risk of CRC incidence was 35.5/1000 persons, and mortality was 7.8/1000 persons. Every month added until colonoscopy was associated with a 0.1/1000 person increase in cancer incidence risk (an increase of 0.3%/month, compared with individuals who received colonoscopies within 2 weeks) and mortality risk (increase of 1.4%/month). Among individuals who received colonoscopy examinations 12 months after a positive result from an FIT, the incidence of CRC was 37.0/1000 persons (increase of 4%, compared with 2 weeks), and mortality was 9.1/1000 persons (increase of 16%). Total years of life gained for the entire screening cohort decreased from an estimated 93.7/1000 persons with an almost immediate follow-up colonoscopy (cost savings of $208 per patient, compared with no colonoscopy) to 84.8/1000 persons with follow-up colonoscopies at 12 months (decrease of 9%; cost savings of $100/patient, compared with no colonoscopy). CONCLUSIONS: By using a microsimulation model of an average-risk United States screening cohort, we estimated that delays of up to 12 months after a positive result from an FIT can produce proportional losses of up to nearly 10% in overall screening benefits. These findings indicate the importance of timely follow-up colonoscopy examinations of patients with positive results from FITs.
BACKGROUND & AIMS: Delays in diagnostic testing after a positive result from a screening test can undermine the benefits of colorectal cancer (CRC) screening, but there are few empirical data on the effects of such delays. We used microsimulation modeling to estimate the consequences of time to colonoscopy after a positive result from a fecal immunochemical test (FIT). METHODS: We used an established microsimulation model to simulate an average-risk United States population cohort that underwent annual FIT screening (from ages 50 to 75 years), with follow-up colonoscopy examinations for individuals with positive results (cutoff, 20 μg/g) at different time points in the following 12 months. Main evaluated outcomes were CRC incidence and mortality; additional outcomes were total life-years lost and net costs of screening. RESULTS: For individuals who underwent diagnostic colonoscopy within 2 weeks of a positive result from an FIT, the estimated lifetime risk of CRC incidence was 35.5/1000 persons, and mortality was 7.8/1000 persons. Every month added until colonoscopy was associated with a 0.1/1000 person increase in cancer incidence risk (an increase of 0.3%/month, compared with individuals who received colonoscopies within 2 weeks) and mortality risk (increase of 1.4%/month). Among individuals who received colonoscopy examinations 12 months after a positive result from an FIT, the incidence of CRC was 37.0/1000 persons (increase of 4%, compared with 2 weeks), and mortality was 9.1/1000 persons (increase of 16%). Total years of life gained for the entire screening cohort decreased from an estimated 93.7/1000 persons with an almost immediate follow-up colonoscopy (cost savings of $208 per patient, compared with no colonoscopy) to 84.8/1000 persons with follow-up colonoscopies at 12 months (decrease of 9%; cost savings of $100/patient, compared with no colonoscopy). CONCLUSIONS: By using a microsimulation model of an average-risk United States screening cohort, we estimated that delays of up to 12 months after a positive result from an FIT can produce proportional losses of up to nearly 10% in overall screening benefits. These findings indicate the importance of timely follow-up colonoscopy examinations of patients with positive results from FITs.
Authors: David A Lieberman; Douglas K Rex; Sidney J Winawer; Francis M Giardiello; David A Johnson; Theodore R Levin Journal: Gastroenterology Date: 2012-07-03 Impact factor: 22.682
Authors: Douglas K Rex; Dennis J Ahnen; John A Baron; Kenneth P Batts; Carol A Burke; Randall W Burt; John R Goldblum; José G Guillem; Charles J Kahi; Matthew F Kalady; Michael J O'Brien; Robert D Odze; Shuji Ogino; Susan Parry; Dale C Snover; Emina Emilia Torlakovic; Paul E Wise; Joanne Young; James Church Journal: Am J Gastroenterol Date: 2012-06-19 Impact factor: 10.864
Authors: Reinier G S Meester; Chyke A Doubeni; Iris Lansdorp-Vogelaar; Christopher D Jensen; Miriam P van der Meulen; Theodore R Levin; Virginia P Quinn; Joanne E Schottinger; Ann G Zauber; Douglas A Corley; Marjolein van Ballegooijen Journal: JAMA Date: 2015-06-16 Impact factor: 56.272
Authors: J D Hardcastle; J O Chamberlain; M H Robinson; S M Moss; S S Amar; T W Balfour; P D James; C M Mangham Journal: Lancet Date: 1996-11-30 Impact factor: 79.321
Authors: Enrique Quintero; Antoni Castells; Luis Bujanda; Joaquín Cubiella; Dolores Salas; Ángel Lanas; Montserrat Andreu; Fernando Carballo; Juan Diego Morillas; Cristina Hernández; Rodrigo Jover; Isabel Montalvo; Juan Arenas; Eva Laredo; Vicent Hernández; Felipe Iglesias; Estela Cid; Raquel Zubizarreta; Teresa Sala; Marta Ponce; Mercedes Andrés; Gloria Teruel; Antonio Peris; María-Pilar Roncales; Mónica Polo-Tomás; Xavier Bessa; Olga Ferrer-Armengou; Jaume Grau; Anna Serradesanferm; Akiko Ono; José Cruzado; Francisco Pérez-Riquelme; Inmaculada Alonso-Abreu; Mariola de la Vega-Prieto; Juana Maria Reyes-Melian; Guillermo Cacho; José Díaz-Tasende; Alberto Herreros-de-Tejada; Carmen Poves; Cecilio Santander; Andrés González-Navarro Journal: N Engl J Med Date: 2012-02-23 Impact factor: 91.245
Authors: Ann G Zauber; Iris Lansdorp-Vogelaar; Amy B Knudsen; Janneke Wilschut; Marjolein van Ballegooijen; Karen M Kuntz Journal: Ann Intern Med Date: 2008-10-06 Impact factor: 25.391
Authors: Jessica Chubak; Michael P Garcia; Andrea N Burnett-Hartman; Yingye Zheng; Douglas A Corley; Ethan A Halm; Amit G Singal; Carrie N Klabunde; Chyke A Doubeni; Aruna Kamineni; Theodore R Levin; Joanne E Schottinger; Beverly B Green; Virginia P Quinn; Carolyn M Rutter Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-02 Impact factor: 4.254
Authors: P Murchie; E A Raja; D H Brewster; N C Campbell; L D Ritchie; R Robertson; L Samuel; N Gray; A J Lee Journal: Br J Cancer Date: 2014-07-03 Impact factor: 7.640
Authors: Reinier G S Meester; Chyke A Doubeni; Ann G Zauber; Marjolein van Ballegooijen; Douglas A Corley; Iris Lansdorp-Vogelaar Journal: Int J Cancer Date: 2017-08-31 Impact factor: 7.396
Authors: Rachel B Issaka; Li Li; Catherine Fedorenko; Cynthia W Ko; John M Inadomi; Scott D Ramsey Journal: J Racial Ethn Health Disparities Date: 2020-02-12
Authors: Jessica Chubak; Melissa L Anderson; Andrea J Cook; Caitlin C Murphy; Michael L Jackson; Beverly B Green Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-05-28 Impact factor: 4.254
Authors: Carolyn M Rutter; Jane J Kim; Reinier G S Meester; Brian L Sprague; Emily A Burger; Ann G Zauber; Mehmet Ali Ergun; Nicole G Campos; Chyke A Doubeni; Amy Trentham-Dietz; Stephen Sy; Oguzhan Alagoz; Natasha Stout; Iris Lansdorp-Vogelaar; Douglas A Corley; Anna N A Tosteson Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-11-17 Impact factor: 4.254
Authors: Gloria D Coronado; Eric S Johnson; Michael C Leo; Jennifer L Schneider; David Smith; Raj Mummadi; Amanda F Petrik; Jamie H Thompson; Ricardo Jimenez Journal: Contemp Clin Trials Date: 2019-12-24 Impact factor: 2.226